| Establishing a clinical execution and CRO support framework for selected bio-health startups
| End-to-end support from IND preparation to clinical trial operations
▲ Kwunho Jeong, CEO of JNPMEDI (left), and Younggu Song, CEO of Yonsei University Bio-Health Technology Holdings,
following the signing ceremony.
JNPMEDI, an AI platform–based company specializing in end-to-end clinical development, announced that it signed a memorandum of understanding (MOU) last month with Yonsei University Bio-Health Technology Holdings to support the clinical entry of technology-driven bio-health startups.
The agreement aims to establish a clinical execution–focused collaboration framework that enables promising companies identified by the technology holdings entity to smoothly enter clinical development and advance toward commercialization. From a CRO perspective, JNPMEDI will directly conduct clinical design and operations, supporting the advancement of each company’s clinical strategy.
Under the MOU, Yonsei University Bio-Health Technology Holdings will identify and recommend companies with strong technological capabilities and growth potential, while JNPMEDI will provide preferential CRO services, including the assignment of a dedicated A-team. Support will cover the full clinical and regulatory lifecycle—from strategy development and IND preparation to clinical trial operations—as well as consulting on preclinical and clinical design, regulatory strategy, and product approval roadmaps. Through this approach, the partnership aims to reduce early-stage trial risks and improve the likelihood of clinical success.
The two parties plan to maintain a close collaboration channel to continuously share insights on promising companies and clinical execution experience, while jointly advancing clinical pipelines from both execution and growth strategy perspectives. JNPMEDI also plans to work closely with funds established by Yonsei University Bio-Health Technology Holdings, strengthening a long-term partnership centered on clinical strategy.
Kwunho Jeong, CEO of JNPMEDI, said, “This agreement is meaningful in helping technology-based companies secure practical execution capabilities at the clinical stage. We will continue to strengthen our role as a CRO partner supporting the entire process from clinical strategy to trial operations.”
| Establishing a clinical execution and CRO support framework for selected bio-health startups
| End-to-end support from IND preparation to clinical trial operations
following the signing ceremony.
JNPMEDI, an AI platform–based company specializing in end-to-end clinical development, announced that it signed a memorandum of understanding (MOU) last month with Yonsei University Bio-Health Technology Holdings to support the clinical entry of technology-driven bio-health startups.
The agreement aims to establish a clinical execution–focused collaboration framework that enables promising companies identified by the technology holdings entity to smoothly enter clinical development and advance toward commercialization. From a CRO perspective, JNPMEDI will directly conduct clinical design and operations, supporting the advancement of each company’s clinical strategy.
Under the MOU, Yonsei University Bio-Health Technology Holdings will identify and recommend companies with strong technological capabilities and growth potential, while JNPMEDI will provide preferential CRO services, including the assignment of a dedicated A-team. Support will cover the full clinical and regulatory lifecycle—from strategy development and IND preparation to clinical trial operations—as well as consulting on preclinical and clinical design, regulatory strategy, and product approval roadmaps. Through this approach, the partnership aims to reduce early-stage trial risks and improve the likelihood of clinical success.
The two parties plan to maintain a close collaboration channel to continuously share insights on promising companies and clinical execution experience, while jointly advancing clinical pipelines from both execution and growth strategy perspectives. JNPMEDI also plans to work closely with funds established by Yonsei University Bio-Health Technology Holdings, strengthening a long-term partnership centered on clinical strategy.
Kwunho Jeong, CEO of JNPMEDI, said, “This agreement is meaningful in helping technology-based companies secure practical execution capabilities at the clinical stage. We will continue to strengthen our role as a CRO partner supporting the entire process from clinical strategy to trial operations.”